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Mini abstract 
The study rationale was to provide a detailed overview of the costs for femoral neck fracture 
treatment with internal fixation in the Netherlands. Mean total costs per patient at two years 
follow-up were €19,425. Costs were higher for older, less healthy patients. Results are 
comparable to internationally published costs.
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Abstract 
 
Purpose: The aim of this study was to provide a detailed overview of the cost and healthcare 
consumption of patients treated for a hip fracture with internal fixation. A secondary aim was 
to compare costs of patients who underwent a revision surgery with patients who did not. 
Methods: The study was performed alongside the Dutch sample of an international 
randomized controlled trial, concerning femoral neck fracture patients treated with internal 
fixation. Patient characteristics and healthcare consumption were collected. Total follow-up 
was two years. A societal perspective was adopted. Costs included hospital costs during 
primary stay and follow-up, and costs related to rehabilitation and changes in living situation. 
Costs were compared between non-revision surgery patients, implant removal patients, and 
revision arthroplasty patients. 
Results: A total of 248 patients were included (mean age 71 years). Mean total costs per 
patient at two years follow-up were €19,425. In the non-revision surgery patients total costs 
were €17,405 (N=137), in the implant removal patients €10,066 (N=38), and in the revision 
arthroplasty patients €26,733 (N=67). The main contributing costs were related to the primary 
surgery, admission days, physical therapy, and revision surgeries. 
Conclusions: The main determinant was the costs of admission to a rehabilitation 
center/nursing home. Costs were specifically high in elderly with comorbidity, who were less 
independent pre-fracture, and have a longer admission to the hospital and/or a nursing home. 
Costs were also higher in revision surgery patients. The two years follow-up costs in our 
study were comparable to published costs in other Western societies. 
Keywords: costs, healthcare consumption, internal fixation, hip fracture, femoral neck 
fracture 
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Introduction 
 
The worldwide incidence of hip fractures is increasing from an estimated 1.26 million patients 
per year in 1990, 1.6 million in 2000, to an estimated 4.5-6.3 million by 2050 [1-3]. 
Accordingly, the incidence of hip fractures in the Netherlands increased from 7,614 per year 
in 1981 to 21,000 per year in 2010 [4, 5]. Globally, the annual estimated worldwide direct and 
indirect costs of hip fractures amounted to $34.8 billion in 1990, and are expected to rise to an 
estimated $131 billion by 2050 [2].  
Detailed information on healthcare costs are gaining importance as the burden of 
health care costs threatens to exceed the financial resources available. It is therefore necessary 
to focus on options to cut down health care expenses. Costs of hip fracture treatment should 
receive attention, as hip fractures account for over two third of all hospital admission days due 
to fractures, the incidence is increasing worldwide, and hip fracture treatment leads to 
substantial costs. In the Netherlands, the total costs of hip fractures amounted to €13.600 per 
patient in 1999 [6]. This was a crude estimate of costs based on national databases and 
registrations, concerning costs of hip fracture patients, treated with various implants and 
prostheses. A number of studies compared the costs of treatment with internal fixation with 
costs of treatment with arthroplasty [7-13]. These studies demonstrated either similar or 
higher costs for patients treated with internal fixation, ranging from €13,000 to €57,197 per 
patient after a two-year follow-up period (Table 1). Comparison between the studies is 
impeded however by the differences in follow-up period and in the costs that were studied. In 
some studies costs were confined to in-hospital health care costs, whereas other studies also 
included costs caused by rehabilitation or changes in living situation. The studies are often 
based on limited patient numbers. It is therefore likely that the presented costs are not all a 
correct estimation of the actual costs involved. To the best of our knowledge, detailed analysis 
 5 
of the costs of internal fixation for hip fractures in the Netherlands has never been performed. 
In the Netherlands, hip fracture care pathways are implemented in an increasing number of 
hospitals, promoting early mobilization, early hospital discharge, and rehabilitation in a 
specialized nursing home department or at home. These pathways are designed to optimize 
patient care and health care cost. 
The aim of this study was to provide a detailed overview of the costs of patients with a 
femoral neck fracture treated with internal fixation. A societal perspective was adopted, 
including costs of health care and costs incurred outside health care. This information can be 
used for economic evaluations. A secondary aim was to compare costs of patients who 
underwent a revision surgery with patients who did not, to study the burden of extra costs 
caused by revision surgeries.
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Patients and Methods 
 
This cost study was a cohort study performed alongside the Dutch sample of the FAITH trial 
(Fixation using Alternative Implants for the Treatment of Hip fractures, NCT00761813), an 
international randomized controlled trial concerning femoral neck fracture patients treated 
with internal fixation. The study was approved by the local medical research ethics 
committee. 
 
Population 
In the Netherlands 14 hospitals participated and enrolled 250 consecutive patients in the 
period between February 2008 and August 2009.  Patients were eligible if they (1) were adults 
aged ≥50 years, (2) had a radiologically confirmed femoral neck fracture (i.e., either 
undisplaced fracture, or displaced fracture in ASA 1-2 patients (American Society of 
Anesthesiologists classification) aged 50-80 years with a fracture that could be reduced 
closed), (3) had a low energy fracture without other major trauma, and (4) were ambulatory 
pre-fracture (with or without aid). Patients were excluded if they (1) had a fracture not 
suitable for internal fixation (e.g,. pathological fracture, rheumatoid arthritis, or 
osteoarthritis), (2) had associated major injuries of the lower extremities, (3) had retained 
hardware around the hip, (4) had an infection around the hip, (5) had a bone metabolism 
disorder other than osteoporosis, (6) were moderately or severely cognitively impaired pre-
fracture, (7) had dementia or Parkinson’s disease severe enough to compromise the 
rehabilitation process, or (8) were not likely to be able to complete follow-up. 
 
Treatment and follow-up 
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All patients had medical optimization before surgery. Patients with undisplaced fractures were 
treated within seven days of presentation, patients with displaced fractures within two days. 
Patients were treated with internal fixation (i.e., either two or three cancellous screws or a 
sliding hip screw). Early mobilization was encouraged, with weight bearing as tolerated. Post-
operative osteoporosis screening and treatment was recommended in all patients. Follow-up 
measurements were performed at 2 weeks, 10 weeks, 6 months, 9 months, 12 months, 18 
months, and 24 months after the primary surgery. 
  
Cost measurement 
The study adopted a societal perspective including the following costs: (1) hospital costs 
during the primary stay, (2) hospital costs during follow-up including cost of hip-related 
adverse events and revision surgeries, and (3) non-hospital costs of rehabilitation and aids. 
(Table 2). Data on resource use were collected prospectively at the scheduled follow-up 
contacts and at the close-out visits at the end of the study. Use of hospital resources was 
collected in the study case report forms (items are listed in supplemental Table 1), and from 
the patient’s hospital file. The latter had 100% capture. These data were supplemented with 
data from a patient self-administered questionnaire, a customized version of the ‘Trimbos and 
iMTA questionnaire on Costs associated with Psychiatric illness’ (Tic-P), which has been 
validated for use in healthcare cost studies [14,15]. An English version of the original Tic-P is 
available online [16].The questionnaire included questions on stay in a rehabilitation center or 
nursing facility, number of contacts with the medical specialist and physical therapist, 
medication and the use of aids (e.g., walker, crutches, and wheelchair). The total number of 
consumption units per cost category per patient was multiplied by the unit prices. The unit 
prices (anno 2010) for all cost categories are presented in Table 2. The costs for use of the 
operating room, including cost for personnel, anesthesia, and overhead costs, as well as 
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implant and general equipment costs were calculated based on data derived from one of the 
participating academic hospitals and three regional hospitals, and one surgical equipment and 
implant firm. Means were calculated and considered a realistic estimation of the average 
prices in the participating sites. 
For most other healthcare resources reference cost prices were derived from the Dutch 
manual on cost research, methods and standard costs in economic healthcare evaluations (17). 
Costs from 2008 and 2009 were adjusted to 2010 terms using the national consumer price 
index. Unit prices for radiologic and other diagnostic procedures were taken from the NZa 
(Nederlandse Zorgautoriteit; Dutch Healthcare Authority) which are assumed to provide a 
good indication of the actual costs. Medication costs were calculated using standard 
medication prices as described by the CVZ (College voor zorgverzekeringen; Health Care 
Insurance Board), online available on www.medicijnkosten.nl (Supplemental Table 2). The 
costs for the use of several aids (i.e., crutches, walker, or extra facilities at home) were 
obtained from at a home care firm that is representative of the Dutch market. These costs were 
used as an estimation of the actual costs for the use of aids in all participating patients, as 
these costs are fairly standard and will not vary to a large extent across the country. Costs of 
aids were calculated according to the annuity method, applying an interest rate of 4.5% and a 
10-year write off period. 
Over 90% of the study population consisted of retired elderly. Consequently, the 
indirect costs due to productivity losses were considered less relevant for this population and 
a minor contribution to the overall costs in this study, and were excluded. Costs of home care 
were also excluded from the analyses. Most elderly patients that received home care were not 
capable of estimating the amount of hours that they received home care. Moreover, it was 
impossible to discriminate home care due to the hip fracture from home care for other medical 
reasons. Reliable cost calculations were therefore impossible. Costs of osteoporosis screening 
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and treatment were included, but not presented as a separate group: costs of a DEXA scan 
were included in radiology/diagnostic studies costs, costs of visits to an osteoporosis 
specialist were included in outpatient clinic visits costs, and costs for osteoporosis treatment 
were included in medication costs. 
 
Statistical analysis 
Analyses were performed using SPSS (version 16.0, SPSS Inc., Chicago, IL, USA). Missing 
values for cost items were replaced using multiple imputation following the predictive mean 
matching method, using ten imputations. Means and standard deviations (SD) were 
calculated. Costs were calculated in the total population and in three subgroups (1) patients 
who did not require a revision surgery, (2) patients who had their implant removed (without 
any other revision surgery), and (3) patients who underwent one or multiple revision 
surgeries. Group 2 consisted of patients with a successfully healed fracture. Patients who had 
other, less common, revision surgeries (i.e., replacement of implant by other implant, shorter 
screw, or revision to gamma nail) were not included in these subgroup-analyses. Costs 
between the subgroups were compared with a one-way ANOVA. Post-hoc comparisons using 
independent samples student T-tests were performed. 
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Results 
 
Demographic description of patients 
Of the 649 consecutive femoral neck fracture patients treated in the study period, 294 patients 
were eligible following the inclusion and exclusion criteria for this study, of which 250 were 
randomized (Figure 1). Two patients could not be followed; one patient turned out not to have 
a femoral neck fracture and one patient withdrew consent immediately after randomization. 
The study group had a mean age of 71 years (SD 10) and 60% was female. Patients 
were relatively healthy and independent pre-fracture. Prior to the fracture only 3% of the 
patients were institutionalized and 13% used an aid for mobilization. Thirteen percent had 
severe comorbidities (i.e., ASA>2). The most common comorbidities were hypertension 
(42%), cardiac disease (21%), or pulmonary disease (16%). Forty-six percent of the fractures 
was displaced (i.e., Garden III-IV) and 35% was a Pauwels 3 fracture. 
 
Treatment and clinical outcome 
Patients were admitted to the hospital during 7 days on average. After discharge, 22% percent 
of the patients rehabilitated in a nursing home, whereas 72% of the patients were able to go 
home. An adverse event occurred in 101 patients (41%), of whom 12 patients had an implant- 
or surgery-related adverse event, and 13 patients sustained a wound infection. Other adverse 
events were a urinary tract infection, delirium, or various non-hip related adverse events, 
which were all infrequent (i.e., less than 10 patients each). In 38 patients (15%) the implant 
was removed after the fracture had healed because of persisting implant-related complaints. A 
revision to an arthroplasty occurred in 67 patients (27%), of which 45 patients received a total 
hip arthroplasty. Out of 67 patients that had a revision to arthroplasty, the revision had been 
performed in 52 patients by one year follow-up, in 36 patients by six months follow-up, and 
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in 23 patients by ten weeks follow-up. The main reason for the revision surgery was the 
occurrence of avascular necrosis and/or non-union. The mean follow-up was 25.5 months (SD 
6.1). 
 
Costs 
An overview of the costs is shown in Table 3. Most costs were generated in the first treatment 
year. The total mean costs per patient at 10 weeks follow-up amounted to €9,781 (SD € 
6,909). The costs in this primary treatment phase were mainly related to the primary surgery 
(mean €1,313; SD € 497), the hospital admission days (mean €4,322; SD €3,104), and the 
admission days in a rehabilitation center or skilled nursing facility after hospital discharge 
(mean €2,735; SD €5,226). 
At one year follow-up, the total mean costs per patient were €16,379 (SD €17,319), 
€6,598 more than at 10 weeks follow-up. The total mean costs per patient in the second year 
of follow-up amounted €3,046. The total mean costs per patient after two years were on 
average €19,425 (SD €24,200). The main contributing cost categories in the first and second 
year of follow-up were similar: (1) the costs related to the admission days in a rehabilitation 
center or skilled nursing facility (i.e., €7,452 per patient in the first year and €1,973 in the 
second year), (2) the costs related to physical therapy at home or in an outpatient physical 
therapy clinic (i.e.,  €1,354 per patient in the first year and €496 in the second year), and (3) 
the costs of revision surgery and related hospital admission days (i.e., €512 per patient in the 
first year and €195 in the second year). In 5 patients, there were extremely high costs for the 
primary hospital admission (i.e., more than €10,000), mainly due to a prolonged length of 
stay. In three patients this was caused by multiple adverse events and revision surgeries, and 
an admission to the ICU. In two patients, no reason could be found for the prolonged length of 
stay. Radiologic studies and other diagnostic studies (i.e., €544; SD 343) and out-patient 
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clinic visits (i.e., €452; SD 267) contributed more than one percent to the total treatment costs 
of the patients at two years follow-up (Figure 2). 
At two years follow-up, the costs were highest for patients who underwent a revision 
to arthroplasty (total mean costs per patient €26,733; SD €24,151) (Table 4). Costs per patient 
were lowest for patients who did not require revision surgery; €17,405 (SD €25,842). Patients 
who had had their implant removed had lower costs (total mean costs per patient €10,066; SD 
€5,484; P 0.001). These differences were seen throughout all follow-up moments.
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Discussion 
 
The total mean costs per femoral neck fracture patient treated with internal fixation were 
€16,379 at one year follow-up and €19,425 at two years follow-up. This is slightly higher than 
the €13,600 estimated in 1999 from national database records, including similar cost 
categories (cost corrected for inflation €17,478, using http://statline.cbs.nl) [6]. One should 
realize that the costs presented include crude costs only, excluding hospital overhead costs 
and taxes, as is usual for economic analyses. This should be taken into account when 
calculating budgets. 
The cost estimates in our study are comparable with previous studies from Western 
societies, although other studies usually did not incorporate all cost categories that were 
included in the present study. This may indicate that the hip fracture care pathways as 
implemented in the Netherlands promoting early mobilization, early hospital discharge, and 
rehabilitation in a specialized nursing home department or at home lead to limited costs. The 
costs in our study are even >50% lower than published costs in 2010 and 2012 for Norway 
(Table 1) [7-13]. Differences can be explained by several factors. The Norwegian studies 
involved older patients, all suffering from displaced fractures, and who were more often 
institutionalized pre-fracture, and less mobile without an aid pre-fracture, with more severe 
comorbidity (including the cognitively impaired). All patients were treated in a university 
hospital, which induces higher costs in general. Additionally, the unit costs per admission day 
to the hospital and to a nursing home were higher in Norway. The revision surgery rate in our 
study was comparable with previously published rates and will therefore not have influenced 
differences in costs between our study and previously published cost data [8, 13, 18-20]. 
The main determinant in the total costs was the costs for admission to a rehabilitation 
facility or nursing home. However, these costs may represent an overestimation of the actual 
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cost related to the hip fracture. It is difficult to determine if the hip fracture was the only 
reason for temporary or permanent stay in a nursing home. Especially in elderly patients this 
is usually multifactorially influenced by general condition, other comorbidities or fractures, 
and the availability of informal care. Another important determinant was the costs for the 
primary hospital admission, similar as reported in other studies. In our study, the length of 
stay was shorter than in some other studies [8, 11, 12]. This distribution of costs in the 
Netherlands seems an effect of the hip fracture care pathways described above. Other 
determinants that substantially contributed to the total costs were the costs for primary surgery 
(7%) and the costs for physical therapy in the out-patient clinic (10%). Reducing the amount 
of physical therapy should not be a focus to reduce costs, as intensive physical therapy has 
proven to benefit patient outcomes and independency [21]. Most costs were generated in the 
first year. In the second year only 16% of the costs were generated. A two years follow-up 
was considered sufficient, as it is known that most interventions, treatments and rehabilitation 
of the targeted patient population will take place in that period [19]. A subset of patients, 
however, will become permanent nursing home residents after their hip fracture, thereby 
extending their societal costs beyond the two years time span. This may not only be caused by 
the hip fracture, as discussed above. 
As expected, costs were highest for patients who underwent a revision to arthroplasty. 
After two years, the costs per patient were on average €9,328 per patient higher than for the 
patients that did not require revision surgery. This amount is in agreement with previous data, 
and is attributed to additional costs for surgery, hospital admission, and rehabilitation [8]. 
Baseline characteristics of the patients that underwent a revision to arthroplasty (i.e., age, 
comorbidity, and pre-fracture living status and mobility) were similar as for patients that did 
not. Costs were lowest for patients who had their implant removed after fracture healing. This 
may seem unexpected, as the implant removal is associated with costs for the surgical 
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intervention. Patient selection is the most likely explanation for the relatively low costs. The 
implant removal patients were younger, healthier, more independent and mobile pre-fracture. 
They therefore probably required less care and rehabilitation, generating less costs. Their 
superior pre-fracture mobility and hence perhaps higher rehabilitation goals may also be an 
indication for their implant removal. Within the patient group that did not have a revision 
surgery, no potential factors were correlated with higher costs other than the previously 
mentioned patient characteristics (i.e., age, ASA score and mobility pre-fracture). 
Our study has some limitations. As the population was relatively young, healthy, and 
independent pre-fracture, the presented costs may not be representative for all hip fracture 
patients. Moreover, not all cost categories related to hip fracture care were included. Costs of 
home care, informal care, and transport could not be reliably reproduced by patients. These 
costs are however expected not to contribute significantly to the total costs, compared with the 
costs that were included. Societal costs due to productivity losses were also excluded, but 
these are not expected to contribute significantly as well as these patients are older and mainly 
retired. Taking these limitations into account, the presented costs are probably an 
underestimation of the actual costs involved, especially for the patients that rehabilitated at 
home. However, the current study is one of few studies analyzing costs of hip fracture 
treatment with internal fixation in detail, including both hospital costs and costs of the 
rehabilitation process. Another strength of our study is the sample size, being the highest of 
all studies published until now. 
 
In conclusion, the total mean costs per femoral neck fracture patient treated with internal 
fixation were €16,379 at one year follow-up and €19,425 at two years follow-up. These costs 
are comparable with costs published from previous studies in Western societies. The hip 
fracture care pathways implemented in the Netherlands promoting early mobilization, early 
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hospital discharge, and rehabilitation in a specialized nursing home department or at home, 
seem successful and contributory to limiting health care costs. Highest costs are generated by 
patients who underwent a revision to arthroplasty. This reinforces the importance of 
attempting to reduce the potentially avoidable risk of a revision surgery by a careful selection 
of patients for internal fixation, not only for medical reasons, but also economical reasons. 
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Tables 
 
Table 1. Studies describing the costs of treatment of femoral neck fracture patients with internal fixation 
Author Country N Follow-up Average costs per patient 
Iorio et al. (2001) US 123 2 yrs €27,474a 
Haentjens et al. (2003) Belgium 14 1 yr €15,255 a 
Rogmark et al. (2003) Sweden 36 2 yrs €18,564  a 
Johansson et al. (2006) Sweden 78 2 yrs €13,100 
Alolabi et al. (2009) Canada 61 1 yr €12,977 a 
Frihagen et al. (2010) Norway 112 2 yrs €47,186 
Waaler Bjørnelv et al. (2012) Norway 86 2 yrs €57,197 
a US Dollars were converted to Euros using year-specific exchange rates (www.statistics.dnb.nl) 
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Table 2. Sources and unit costs (2010) of healthcare resources 
Cost categories Unit Source of consumption data Source of valuation Unit price (€) 
Hospital costs – primary stay 
Emergency department visit 
Radiology/Diagnostic studies 
X-ray 
CT-scan pelvis 
MRI scan pelvis 
Ultrasound 
DEXA scan 
Skeletal scintigraphy 
Surgery 
Surgeon 
Operating room* 
Additional costs after hours 
Equipment and implant 
 
Visit 
 
X-ray 
CT-scan 
MRI scan 
Ultrasound 
DEXA scan 
Scintigraphy 
 
Hour 
Hour 
Hour 
 
 
Hospital registry 
 
Hospital registry 
Hospital registry 
Hospital registry 
Hospital registry 
Hospital registry 
Hospital registry 
 
Study registry (Case report Form) 
Study registry (Case report Form) 
Study registry (Case report Form) 
 
 
Cost manual1 
 
NZa2 
NZa2 
NZa2 
NZa2 
NZa2 
NZa2 
 
Cost manual1 
Hospital/industry data3 
Hospital/industry data3 
 
 
152.92 
 
51.63 
227.22 
261.47 
82.09 
109.22 
185.37 
 
137.22a / 104.31b 
560.94a / 704.51b 
75.36a/ 94.65b 
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Cancellous screws 
Sliding Hip Screw 
Admission days 
Operation 
Operation 
Day 
Study registry (Case report Form) 
Study registry (Case report Form) 
Study registry (Case report Form) 
Hospital/industry data3 
Hospital/industry data3 
Cost manual1 
490.30 
504.91 
440.53a / 582.31b 
Hospital costs – follow-up 
Radiology/Diagnostic studies 
Out-patient clinic visits 
Adverse events 
Medication** 
Emergency department visit 
Admission days 
Revision surgery 
Surgeon 
Operating room* 
Equipment and implant 
Hemiarthroplasty 
Total Hip Arthroplasty 
 
 
Visit 
 
Dose per day 
Visit 
Day 
 
Hour 
Hour 
 
Operations 
Operations 
 
 
Hospital registry + patient questionnaire§ 
 
Hospital registry + patient questionnaire§ 
Hospital registry 
Study registry (Case report Form) 
 
Study registry (Case report Form) 
Study registry (Case report Form) 
 
Study registry 
Study registry 
 
 
Cost manual1 
 
CVZ4 
Cost manual1 
Cost manual1 
 
Cost manual1 
Hospital/industry data3 
 
Hospital/industry data3 
Hospital/industry data3 
 
As described above 
130.64a / 64.81b 
 
N.A. 
152.92 
440.53a / 582.31b  
 
137.22a / 104.31b 
560.94a / 704.51b 
 
1685.64 
1722.39 
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Gammanail 
Extended gammanail 
Implant removal 
Soft tissue debridement 
Antibiotic beads 
Antibiotic spacer 
Admission days 
Medication*** 
Operations 
Operations 
Operations 
Operations 
Operations 
Operations 
Day 
Dose per day 
Study registry 
Study registry 
Study registry 
Study registry 
Study registry 
Study registry 
Study registry (Case report Form) 
Hospital registry + patient questionnaire§ 
Hospital/industry data3 
Hospital/industry data3 
Hospital/industry data3 
Hospital/industry data3 
Hospital/industry data3 
Hospital/industry data3 
Cost manual1 
CVZ4 
1241.51 
1258.39 
53.16 
25.29 
567.79 
496.26 
440.53a / 582.31b  
N.A. 
Costs related to rehabilitation /  
changes in living situation 
Rehabilitation center/Nursing home 
Elderly home 
Nursing home 
Rehabilitation clinic 
Home nursing day 
Physical therapy (outpatient) 
 
 
 
Days 
Days 
Days 
Hours 
 
 
 
 
Patient questionnaire§ 
Patient questionnaire§ 
Patient questionnaire§ 
Patient questionnaire§ 
 
 
 
 
Cost manual1 
Cost manual1 
Cost manual1 
Cost manual1 
 
 
 
 
91.14 
241.03 
344.32 
35.44 
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Physical therapy 
Mensendieck / Cesar therapy 
Use of aids 
Crutches 
Walker 
Wheelchair 
Electric scooter 
Extra bed 
Extra toilet facilities 
Extra shower facilities 
Session 
Session 
 
Day 
Day 
Day 
Day 
Day 
Day 
Day 
Patient questionnaire§ 
Patient questionnaire§ 
 
Patient questionnaire§ 
Patient questionnaire§ 
Patient questionnaire§ 
Patient questionnaire§ 
Patient questionnaire§ 
Patient questionnaire§ 
Patient questionnaire§ 
Cost manual1 
Cost manual1 
 
Home care firm5 
Home care firm5 
Home care firm5 
Home care firm5 
Home care firm5 
Home care firm5 
Home care firm5 
36.46 
35.45 
 
0.07 
0.08-0.14 
0.25 
0.66 
1.15 
0.09-0.19 
0.09-0.17 
N.A.; Not applicable 
Reference unit costs anno 2010 were used, or costs were adjusted to 2010 costs using the national consumer price index. 
*Including operating room personnel, anesthesia, and overhead costs. **Mainly antibiotics. ***Hip fracture related medication only (i.e., pain 
medication and osteoporosis medication; see Supplemental Table 2 for details). 
§ Patient questionnaire; Customized version of the ‘Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness’. 
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1 Cost manual; Manual on cost research, methods and standard costs in economic healthcare evaluations, version 2010 (17), 2 NZa; Nederlandse 
Zorgautoriteit (Dutch Healthcare Authority) standard costs. 3 Hospital/industry data; costs were requested from one academic hospital, three 
regional hospitals, and one surgical equipment and implant firm. Means were calculated and used as an estimation of the real costs in all 
participating sites. 4 CVZ; Standard prices were used as described by the CVZ (College voor zorgverzekeringen; Health Care Insurance Board), 
online available on www.medicijnkosten.nl. 5 Home care firm; costs of aids were requested from a home care firm and costs per day were 
calculated based on the calculated daily annuity. These costs were used as an estimation of the real costs in all participating patients. 
a Academic hospital, b General hospital. 
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Table 3. Mean costs of femoral neck fracture patients treated with internal fixation (N=248) 
Cost categories Cost until 10 weeks (€) Costs until 1 year (€) Costs until 2 years (€) 
Hospital costs – primary stay 
Emergency department visit 
Radiology/Diagnostic modalities 
Surgery 
Admission days 
Total 
 
152 (152-152) 
243 (207-361) 
1,313 (793-2,506) 
4,322 (1,762-9,287) 
6,031 (3,392-11,090) 
 
152 (152-152) 
243 (207-361) 
1,313 (793-2,506) 
4,322 (1,762-9,287) 
6,031 (3,392-11,090) 
 
152 (152-152) 
243 (207-361) 
1,313 (793-2,506) 
4,322 (1,762-9,287) 
6,031 (3,392-11,090) 
Hospital costs – follow-up 
Radiology/Diagnostic modalities 
Out-patient clinic visits 
Adverse events 
Revision surgery 
Medication 
Total 
 
212 (103-472) 
134 (65-261) 
39 (0-45) 
154 (0-1500) 
30 (0-112) 
568 (168-1,989) 
 
441 (127-981) 
370 (165-792) 
54 (0-111) 
512 (0-2,117) 
88 (0-324) 
1,465 (378-4171) 
 
544 (207-1,163) 
452 (194-1,023) 
128 (0-697) 
707 (0-2,287) 
157 (0-555) 
1,988 (480-4,838) 
Costs related to rehabilitation /     
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changes in living situation 
Rehabilitation center/Nursing home 
Physical therapy (outpatient) 
Use of aids 
Total 
 
2,735 (0-15,076) 
418 (0-1006) 
28 (5-104) 
3,181 (27-15,782) 
 
7,452 (0-39,991) 
1,354 (231-3,169) 
76 (5-245) 
8,883 (487-41,743) 
 
9,425 (0-46,308) 
1,850 (292-4,752) 
131 (5-466) 
11,406 (540-51,300) 
Total costs 9,781 (3,993-24,203) 16,379 (4,977-52,339) 19,425 (5,237-58,874) 
Costs are presented as cumulative mean costs at each follow-up moment with 95% confidence interval between brackets. 
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Table 4. Costs of patients without revision surgery, patients who had an implant removal, and patients who required revision surgery 
 
 No revision surgery 
(N=137) 
Implant removed* 
(N=38) 
Revision surgery to arthroplasty 
(N=67) 
P-value 
Costs until 10 wks 9,371 (3,970-24,339) 6,967 (3,394-19,322) 11,549 (5,125-29,762) 0.003 
Costs until 1 year 14,438 (4,824-45,211) 8,723 (4,434-19,735) 22,498 (8,052-73,307) <0.001 
Costs until 2 years 17,405 (4,953-58,865) 10,066 (4,843-26,731) 26,733 (9,465-80,029) 0.001 
Costs are presented as cumulative mean costs at each follow-up moment with standard deviations between brackets. 
Differences between the three groups were compared with a one-way ANOVA. Post-hoc comparisons using independent samples student T-tests 
were performed and indicated that all subgroups had significant differences in costs at all follow-up moments (i.e., P<0.005). 
Six patients were excluded from the subgroup analyses as these patients all had other, less common, revision surgeries (i.e., replacement of 
implant by other implant, shorter screw, or revision to gamma nail) 
* This group consisted of patients that healed successfully.
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Figures 
 
Figure 1. Flowchart of patients participating in the study 
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Figure 2. Relative contribution of various cost categories to the total treatment costs of patients until two years follow-up. 
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